{"groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"FG000","title":"Pazopanib 800 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Sponsor Terminated Study"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"80"}],"type":"STARTED"},{"achievements":[{"comment":"Participants completed treatment (until disease progression), but may not have completed the study.","groupId":"FG000","numSubjects":"49"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}